Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor Positive，HER2-negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06388122
What this trial is testing

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

Who this might be right for
HER2-negative Breast CancerHormone-receptor-positive Breast CancerMetastatic Breast Cancer+6 more
Mayo Clinic 100
Early research (Phase 1)Ended earlyNCT05194072
What this trial is testing

Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Who this might be right for
Ovarian NeoplasmsPeritoneal NeoplasmsFallopian Tube Neoplasms+8 more
Seagen, a wholly owned subsidiary of Pfizer 250
Large-scale testing (Phase 3)Looking for participantsNCT06966700
What this trial is testing

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Who this might be right for
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC 2,400
Testing effectiveness (Phase 2)Study completedNCT03078751
What this trial is testing

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 54
Large-scale testing (Phase 3)Active Not RecruitingNCT01272037
What this trial is testing

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Who this might be right for
Breast Ductal Carcinoma In SituInvasive Breast CarcinomaMulticentric Breast Carcinoma+2 more
National Cancer Institute (NCI) 5,018
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07658183
What this trial is testing

A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer (Locally Advanced or Metastatic)
Shanghai Best-Link Bioscience, LLC 120
Large-scale testing (Phase 3)Looking for participantsNCT06380751
What this trial is testing

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 788
Testing effectiveness (Phase 2)Study completedNCT03809988
What this trial is testing

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

Who this might be right for
Breast CancerAdvanced Breast CancerHormone Receptor Positive Tumor+1 more
MedSIR 198
Large-scale testing (Phase 3)UnknownNCT02404051
What this trial is testing

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerBreast CancerHormone Receptor Positive Tumor+2 more
Consorzio Oncotech 745
Testing effectiveness (Phase 2)Ended earlyNCT02269670
What this trial is testing

Phase II Study of Everolimus Beyond Progression

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerProgesterone Receptor-positive Breast Cancer+5 more
Emory University 3
Early research (Phase 1)Study completedNCT02333370
What this trial is testing

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Who this might be right for
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Novartis Pharmaceuticals 88
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Testing effectiveness (Phase 2)Looking for participantsNCT06970912
What this trial is testing

CtDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

Who this might be right for
Hormone Receptor-Positive Breast CancerHigh-risk Breast CancerEarly-Stage Breast Cancer+3 more
Peking University People's Hospital 393
Testing effectiveness (Phase 2)Looking for participantsNCT05582499
What this trial is testing

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Who this might be right for
Breast NeoplasmBreast CancerBreast Tumors+7 more
Fudan University 716
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07336771
What this trial is testing

JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast Cancer (LABC)
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 60
Not applicableStudy completedNCT05155566
What this trial is testing

Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.

Who this might be right for
Breast Cancer Metastatic
Pfizer 847
Early research (Phase 1)Study completedNCT05759949
What this trial is testing

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Who this might be right for
PIK3CA MutationSolid Tumor, AdultHER2-negative Breast Cancer+5 more
Relay Therapeutics, Inc. 41
Testing effectiveness (Phase 2)Looking for participantsNCT06179303
What this trial is testing

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Unresectable HER2-Negative Breast Carcinoma+3 more
University of Washington 60
Early research (Phase 1)WithdrawnNCT04498520
What this trial is testing

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+32 more
Pamela Munster
Not applicableLooking for participantsNCT03723928
What this trial is testing

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor PositiveHER2/Neu Negative+3 more
SWOG Cancer Research Network 739
Next Page